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Lipoproteins Are Associated With Young
Age in Patients With Acute Myocardial Infarction
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Dijon, France
Objectives Our aim was to characterize cholesteryl ester transfer protein (CETP) activity in the early phase of acute myocar-
dial infarction (MI).
Background Cholesteryl ester transfer protein catalyzes the transfer of cholesteryl esters from high-density lipoprotein (HDL)
donors to apolipoprotein B-containing lipoprotein acceptors.
Methods The CETP concentration, lipid profiles, and the rate of cholesteryl ester transfer (CET) from a tracer dose of radio-
labeled HDL toward endogenous lipoproteins were determined within 24 h after symptom onset.
Results Among 347 patients with first MI, CETP concentration, triglycerides, and non–HDL-cholesterol increased across
tertiles of the CET rate, whereas HDL-cholesterol, HDL, and LDL sizes decreased gradually. Among lipoprotein
donors and acceptors, the best predictors of the CET rate were HDL2b and non–HDL-cholesterol, respectively.
Mean age at first MI was 8.5 years lower in the patients from the highest CET tertile than in those in the lowest
CET tertile. Diagonal stratification according to both non–HDL-cholesterol and HDL2b tertiles revealed that pa-
tients in the highest CET group were 18 years younger than patients in the lowest CET group. Parameters of the
high CETP mass/high non–HDL-cholesterol/low HDL2b triad were independently associated with the CET rate.
Conclusions In patients with acute MI, high CET rates are characterized by the presence of the high CETP mass/high non–
HDL-cholesterol/low HDL2b triad. The association of high CET rates with young age at first MI lends support to
a significant contribution of CETP to the accelerated progression of disease among asymptomatic patients.
(J Am Coll Cardiol 2007;50:1948–55) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.052c
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slasma cholesteryl ester transfer protein (CETP) catalyzes
he exchange of cholesteryl esters and triglycerides between
irculating lipoproteins, leading to the net mass transfer of
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ccepted June 11, 2007.holesteryl esters from antiatherogenic high-density lipo-
roteins (HDL) to proatherogenic apolipoprotein (apo)
-containing lipoproteins (very-low-density lipoproteins
VLDL] and low-density lipoproteins [LDL]). Although
he reduction in plasma neutral lipid transfer activity, as a
See page 1956
esult of either CETP gene mutation (1) or CETP inhibi-
ion (2), is known to produce a major yet unrivaled increase
n HDL-cholesterol, its impact on atherosclerosis preven-
ion still remains a matter of debate. In particular, animal
tudies have provided a mixed picture (3). Whether modu-
ation of CETP is beneficial or deleterious in the prevention
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November 13, 2007:1948–55 CETP and Myocardial Infarctionr treatment of cardiovascular disease has recently come to
he fore, because an excess of deaths and cardiovascular
vents has been found in high-risk patients from the
LLUMINATE (Investigation of Lipid Level management
o Understand its iMpact IN ATherosclerotic Events) study
eceiving the CETP inhibitor torcetrapib (3). This outcome
as rather unexpected, at least in the light of 3 distinct but
omplementary observations. First, elevated CETP mass
nd activity had been reported in patients with a history of
yocardial infarction (MI) (4) in whom CETP-mediated
ecreases in the levels of large LDL and HDL subfractions
orrelated with cardiovascular risk (5,6). Second, CETP-
eficient subjects with high HDL-cholesterol have a lower
ncidence of coronary heart disease (CHD) than subjects
ith normal CETP activity (7), whereas subjects with
igh CETP concentrations have an increased risk for
uture CHD (8). Third, CETP was reported to relate to
he progression of atherosclerosis in high-risk popula-
ions (9 –11). It remains plausible that torcetrapib was
armful in the ILLUMINATE study not because of its
mpact on the lipoprotein profile but because of uncon-
rolled molecule-specific adverse effects (12–14). Based
n these observations, the hypothesis of a predominant
dverse effect of CETP still deserves attention, at least in
igh-risk populations.
An independent yet unexplored way to answer the ques-
ion of the role of CETP in cardiovascular disease would be
o assess further whether elevated CETP activity was
ssociated with a younger age at first MI onset. To this end,
ETP concentrations and cholesteryl ester transfer (CET)
ates were measured in patients with acute MI at the very
arly phase, during which changes in lipids and CET rates
re minimal (15,16). The hallmarks of elevated CET rates,
ncluding high triglycerides and small LDL and HDL were
etermined.
ethods
atients. From April 2004 to December 2005, all of the
onsecutive patients hospitalized in the coronary care unit of
he University Hospital of Dijon for acute MI and fulfilling
he inclusion criteria were included. Eligible patients were
dentified during the index admission, and medical records
ere reviewed on an ongoing basis after appropriate consent
ad been obtained. The hospital list of discharged patients
as systematically reviewed to validate a posteriori eligible
ases with the use of the International Classification of
iseases (ICD)-9 codes 410 and 411 and the corresponding
odes in ICD-10. Standardized definitions for MI, patient-
elated variables and clinical outcomes were used. Patients
ere enrolled if they were age 18 years or older and
dmitted to the center within 24 h of the onset of symptoms
ith a suspected diagnosis of MI. Patients with a history of
ardiovascular disease (prior MI, documented CHD, or
eripheral arterial disease) were excluded from the main
nalysis. However, they were included in a subsidiary cnalysis to ascertain whether the
bservations applied to the whole
opulation of patients hospital-
zed for MI. A final diagnosis of
I was made in the presence of
erial increases in serum biochem-
cal markers of cardiac necrosis,
ssociated with typical electrocar-
iographic changes and/or typical
ymptoms (17).
Patients’ characteristics, car-
iovascular risk factors, chronic
herapy, and medical history
ere collected prospectively,
long with baseline clinical data.
he cases were ascertained by the
rospective collection of consec-
tive admissions. The study
omplied with the Declaration of
elsinki and was approved by
he ethics committee of the Cen-
re Hospitalier Universitaire de Dijon. Each patient gave
ritten informed consent before participation.
iochemical analyses. Fasting blood samples were col-
ected in glass tubes on the morning after admission.
edian (interquartile range [IQR]) time from symptom
nset to blood sampling was 16 (8 to 30) h. Patients
ampled after 24 h (34%) were taken into account in the
nalysis. Serum total cholesterol, triglyceride, and HDL-
holesterol concentrations were determined on a Dimension
pand (Dade Behring, Marburg, Germany) using enzy-
atic methods. Non–HDL-cholesterol was calculated by
ubtracting HDL-cholesterol from total cholesterol. The
DL cholesterol was calculated according to the Friedewald
ormula. The CETP concentration was measured by a
pecific enzyme-linked immunosorbent assay with TP1
nti-CETP antibodies (18). Serum CET activity was de-
ermined from 3H-CE-HDL toward endogenous serum
poB-containing lipoproteins (19–21). The CET rates are
xpressed in nmoles cholesteryl esters transfered per ml
erum per hour. The size distribution of lipoproteins was
nalyzed by electrophoresis on Spiragel 1.5% to 25.0%
Spiral, Couternon, France) (22). The relative proportions
f serum HDL subfractions (HDL2b, 9.71 to 12.90 nm;
DL2a, 8.77 to 9.71 nm; HDL3a, 8.17 to 8.77 nm;
DL3b, 7.76 to 8.17 nm; and HDL3c, 7.21 to 7.76 nm)
ere obtained by determining the relative areas under the
can curve and by relating them to the total area correspond-
ng to the entire serum HDL fraction (22).
tatistical analysis. Data are shown as mean  SD or
edian (IQR), as appropriate, and qualitative data are
resented as frequencies. Dichotomic data were compared
y the chi-square test for trends across tertiles and by the
hi-square test for comparison between 2 groups. For
ontinuous variables, the normality of distribution was
Abbreviations
and Acronyms
apoB  apoliprotein B
BMI  body mass index
CET  cholesteryl ester
transfer
CETP  cholesteryl ester
transfer protein
CHD  coronary heart
disease
HDL  high-density
lipoprotein
ICD  International
Classification of Diseases
LDL  low-density
lipoprotein
MI  myocardial infarction
VLDL  very-low-density
lipoproteinshecked by the Kolmogorov-Smirnov test. In our data-
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CETP and Myocardial Infarction November 13, 2007:1948–55et, only total cholesterol, CETP concentration, HDL2b,
nd HDL3b were non-normally distributed. Log-
ransformation of the skewed data was used for univariate
Pearson correlation and Student t test) and multivariate
multiple linear regression) analyses for prediction of the
ET rate. For all of the other analyses, nonparametric
ests for skewed data or parametric tests for normally
istributed values were performed on untransformed
alues. For 2-group comparisons, values were tested by either
he Mann-Whitney rank-sum test or the Student t test. For
he tests across tertiles, we performed either the Kruskal-Wallis
-way analysis of variance by rank or 1-way analysis of variance
s appropriate. Univariate relationships between the CET
ate, as a dependent variable, and clinical parameters were
nalyzed by either the Student t test for binary variables
gender, history of diabetes, hypertension, smoking, fibrate)
r by the Pearson correlation test for continuous variables
age, BMI, blood lipid parameters). Multiple linear regres-
ion analysis (models 1 and 2) were performed with the
ET rate as a dependent variable. Variables entered into the
odels were those with a significant relationship (p 0.05)
ith the dependent variable in univariate analysis. Model 1
ncluded age, gender, smoking, fibrate, triglycerides, CETP
oncentration, non–HDL-cholesterol, and HDL. Model 2
ncluded age, gender, smoking, fibrate, triglycerides, CETP
oncentration, non–HDL-cholesterol, and HDL2b. The
ssumption of linearity for continuous independent variables
nd constant variance of the standardized residuals were
ssessed by plotting the residuals against fitted values.
wo-sided p values of 0.05 were considered to be statis-
ically significant.
esults
haracteristics of patients. Table 1 presents the charac-
eristics of the patients without a history of cardiovascular
isease (n  347), classified according to tertiles of serum
ET rates (low, medium, and high). Gender, hypertension,
nd diabetes, as well as hypolipidemic therapy (including
tatins and fibrates) were similar for all tertiles. The pro-
ortion of current smokers increased gradually across the
Baseline Characteristics According to CET Rate
Table 1 Baseline Characteristics According
CET Rate Tertile
Low, 1.20–6.83
(n  116)
Me
Age at MI onset, yrs 66.5  14.0
Female 40 (34%)
BMI, kg/m2 29.4  11.6
Hypertension 51 (44%)
Diabetes 19 (16%)
Current smoking 29 (25%)
Fibrate 15 (13%)
Statin 12 (10%)
Values are presented as mean  SD, median (interquartile range), or
continuous data, either the Kruskal-Wallis 1-way analysis of variance by rank
BMI  body mass index; CET  cholesteryl ester transfer; MI  myocardiaertiles, with one-quarter in the lowest to almost one-half in
he highest tertile. Strikingly, age at first MI markedly
ecreased across tertiles: mean age in the highest tertile
as 8.5 years lower than that in the lowest (p  0.001)
Table 1).
erum lipid parameters. Serum values did not differ sig-
ificantly whether admission to hospital was within the first
r the second half of the 24-h period after symptom onset,
n particular for CET rates (8.31  2.54 nmol/ml/h vs.
.93  3.56 nmol/ml/h, respectively; p  0.553). This
ndicates that the time of sampling when performed early
24 h) after hospital admission did not constitute a
onfounding parameter in the present study. The 2.2-fold
ncrease in the CET rate between the low and the high
ubgroups was associated with a moderate but significant
ise in plasma CETP concentration (Table 2). Striking
ncreases in the triglycerides-to-LDL-cholesterol and
riglycerides-to-HDL-cholesterol ratio were observed from
he lowest to the highest tertile of the CET rates. These
hanges were accompanied by concomitant decreases in
DL-cholesterol concentrations (p  0.001 in all cases).
ipoprotein size distribution. The relative abundance of
he small-sized HDL3a, HDL3b, and HDL3c subpopula-
ions increased gradually across tertiles of the CET rates
Table 2). This occurred at the expense of the large HDL2
ubpopulations, mainly HDL2b, which were 35% lower in
he high tertile than in the low. At the same time, a slight
ecrease in mean LDL diameter was observed (Table 2).
actors associated with CET rate. Spearman correlation
howed an inverse relationship between the serum CET rate
nd HDL-cholesterol concentration, but a positive relation-
hip between the CET rate and both non–HDL-cholesterol
nd triglyceride concentrations (Table 3). Compared with
orrelations of CET rates with other parameters, a slightly
igher correlation coefficient was observed with the
riglycerides-to-HDL-cholesterol ratio, which combines
onor and acceptor lipoprotein parameters (Table 3). As a
esult of changes in lipid fluxes between HDL and apoB-
ontaining lipoproteins, the CET rate correlated with the
ize of both LDL and HDL. Among lipoprotein donor
ET Rate
ge (Min–Max, nmol/ml/h)
p Value
6.87–9.10
116)
High, 9.17–18.80
(n  115)
 13.6 58.0  13.8 0.001
(26%) 24 (21%) 0.062
 4.6 28.2  4.7 0.01
(45%) 50 (43%) 0.978
(17%) 13 (11%) 0.394
(31%) 54 (47%) 0.002
(11%) 6 (5%) 0.118
(10%) 10 (9%) 0.888
ichotomic data were compared by the chi-square test for trends. Forto C
, Ran
dium,
(n 
63.7
30
26.3
52
20
36
13
12
n (%). D
or 1-way analysis of variance was used as appropriate.
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November 13, 2007:1948–55 CETP and Myocardial Infarctionarameters, HDL2b showed the strongest correlation with
ET rates. Among lipoprotein acceptor parameters, non–
DL-cholesterol was the best predictor of the CET rate
Table 3).
The associations between patient characteristics, lipid
arameters, and the CET rate are shown in Table 4.
nivariate analysis revealed that the CET rate was related
o age, gender, smoking, fibrate therapy, lipoprotein param-
ters and CETP concentration. Multivariate analysis was
Distribution of Blood Lipid Parameters Accordin
Table 2 Distribution of Blood Lipid Paramete
CET Rate Te
Low, 1.20–6.83
(n  116)
Total cholesterol, mg/dl 181 38
LDL-cholesterol, mg/dl 115 36
HDL-cholesterol, mg/dl 44 14
Non–HDL-cholesterol, mg/dl 136 37
Triglycerides, mg/dl 107 76
TG:HDL-cholesterol ratio 2.82 2.86
TG:LDL-cholesterol ratio 1.00 0.81
CETP concentration, mg/l 2.59 0.54
CET rate, nmol/ml/h 5.36 1.25
HDL2a, % 28.6 4.2
HDL2b, % 20.9 6.8
HDL3a, % 25.6 3.8
HDL3b, % 15.4 4.2
HDL3c, % 9.6 3.7
LDL size, nm 25.6 0.5
Values are presented asmean SD. Dichotomic data were compared b
1-way analysis of variance by rank or 1-way analysis of variance was
CET  cholesteryl ester transfer; CETP  cholesteryl ester transfer
triglycerides.
earson Correlation Analysis for thessociation of CET Rate and Biologic Parameters
Table 3 Pearson Correlation Analysis for theAssociation of CET Rate and Biologic Parameters
r p Value
Patient characteristics
Age at MI onset 0.246 0.001
BMI 0.070 0.196
CETP parameters
CETP concentration 0.369 0.001
Lipoprotein acceptor parameters
Triglycerides 0.462 0.001
LDL-cholesterol 0.390 0.001
Non–HDL-cholesterol 0.495 0.001
LDL size 0.285 0.001
TG:HDL-cholesterol ratio 0.518 0.001
TG:LDL-cholesterol ratio 0.213 0.001
Lipoprotein donor parameters
HDL-cholesterol 0.373 0.001
HDL2a 0.236 0.001
HDL2b 0.452 0.001
HDL3a 0.273 0.001
HDL3b 0.389 0.001
HDL3c 0.254 0.001c
on-normally distributed data were log-transformed before being entered into the analysis.
Abbreviations as in Tables 1 and 2.hen performed by including variables with significant
elationships in univariate analysis, and 2 models were built
ncluding either HDL-cholesterol (model 1) or HDL2b
model 2) as lipoprotein donors. The HDL2b, CETP mass
oncentration, and non–HDL-cholesterol were strong and
ndependent predictors of the CET rate. Moreover, the
on–HDL-cholesterol/CETP mass/HDL2b combination
etter predicted the CET rate than did the non–HDL-
holesterol/CETP mass/HDL-cholesterol combination (r2 
.51 vs. r2  0.33, respectively). When LDL cholesterol was
sed instead of non–HDL-cholesterol in multiple linear
egression analysis, the regression coefficient (SE) was 0.327
0.083; p  0.001) instead of 0.394 (0.104; p  0.001) in
odel 1 and 0.357 (0.066; p  0.001) instead of 0.438
0.851; p  0.001) in model 2, respectively. Overall, r2 in
odel 1 and model 2 was similar when using either LDL
holesterol or non–HDL-cholesterol in the analysis (model
: r2  0.335 vs. r2  0.327; model 2: r2  0.534 vs. r2 
.512, respectively).
ge at first MI and CET rate. Among MI patients, age at
rst MI onset correlated positively with antiatherogenic
DL-related parameters, but negatively with cardiovascular
isk factors such as total cholesterol, non–HDL-cholesterol,
nd triglycerides (Table 5). The correlation coefficient of the
erum CET rate with the triglycerides-to-HDL-cholesterol
atio was only slightly higher than that obtained with either
arameter alone (Table 5). By multiple linear regression, age
t first MI as a dependent variable was predicted from a
inear combination of triglycerides and CET rates as inde-
endent variables (regression coefficients [SE] 3.17 [0.89;
 0.001] and 0.56 [0.28; p  0.045], respectively).
Diagonal stratification according to both non–HDL-
he CET Rate
ccording to the CET Rate
Range (Min–Max, nmol/ml/h)
p Value
ium, 6.87–9.10
(n  116)
High, 9.17–18.80
(n  115)
205 40 220 44 0.001
140 34 152 39 0.001
42 13 33 12 0.001
164 35 187 42 0.001
117 51 192 123 0.001
.25 2.15 6.92 5.79 0.001
.89 0.46 1.26 0.71 0.001
.82 0.59 2.99 0.65 0.005
.92 0.62 11.57 2.53 0.001
7.7 3.5 26.4 5.7 0.001
8.4 5.7 13.6 6.0 0.001
7.0 4.1 28.2 4.8 0.001
7.1 3.6 19.5 5.1 0.001
0.0 3.7 12.2 5.3 0.001
5.6 0.5 25.2 0.6 0.001
i-square test for trends. For continuous data, either the Kruskal-Wallis
s appropriate.
HDL  high-density lipoprotein; LDL  low-density lipoprotein; TG g to t
rs A
rtile,
Med
3
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CETP and Myocardial Infarction November 13, 2007:1948–55owest CET rates were found in patients with the lowest
on–HDL-cholesterol and the highest HDL2b levels,
hereas the highest CET rates were found in patients with
he highest non–HDL-cholesterol and the lowest HDL2b
evels. Most strikingly, in patients with the highest CET
ate (11.95  3.97 nmol/ml/h), the age at first MI was on
verage 18 years lower than that in patients with the lowest
ET rate (5.65  2.32 nmol/ml/h [p  0.001]; 54  14
ears vs. 72  12 years [p  0.001]) (Fig. 1).
Current smoking and abnormal blood lipids are the 2
ain features of young patients with acute MI. Moreover,
nivariate and Multivariate Analyses for the Association Between tate, as a Dependent V riable, and Patients’ Characteristics or Lip
Table 4 Univariate and Multivariate Analyses for the AssociatioRate, as a Dependent Variable, and Patients’ Characte
Variable
Median (IR) CET
Rate
Univariate*
p Value
R
C
Age at MI onset — 0.001
Gender (F, M) 7.6 (6.0–9.2),
7.9 (6.6–10.2)
0.028
Smoking (Y, N) 8.6 (7.0–10.8),
7.6 (6.2–9.2)
0.001
Fibrate (Y, N) 7.1 (5.5–8.1),
7.9 (6.4–10.0)
0.020
Lipoprotein acceptor parameters
Non–HDL-cholesterol — 0.001
Triglycerides — 0.001
Lipoprotein donor parameters
HDL-cholesterol — 0.001
HDL2b — 0.001
CETP parameter
CETP concentration — 0.001
R2
Univariate analysis: Pearson correlation (age, BMI, blood lipid parameters) or Student t test (gend
on-normally distributed data were log-transformed before being entered into the Pearson correla
Abbreviations as in Tables 1 and 2.
earson Correlation Analysis for the Associationor Age at MI Onset a d Biologic Parametersn  347)
Table 5
Pearson Correlation Analysis for the Association
for Age at MI Onset and Biologic Parameters
(n  347)
r p Value
Total cholesterol 0.228 0.001
LDL-cholesterol 0.206 0.001
HDL-cholesterol 0.218 0.001
Non–HDL-cholesterol 0.291 0.001
Triglycerides 0.296 0.001
TG:HDL-cholesterol ratio 0.306 0.001
TG:LDL-cholesterol ratio 0.166 0.002
CETP concentration 0.086 0.299
CET rate 0.261 0.001
HDL2a 0.004 0.469
HDL2b 0.318 0.001
HDL3a 0.221 0.001
HDL3b 0.254 0.001
HDL3c 0.055 0.319
LDL size 0.189 0.001on-normally distributed data were log-transformed before being entered into the analysis.
Abbreviations as in Tables 1 and 2.ypolipidemic treatments (statins and fibrates) may influ-
nce CET rates through modifications in the concentrations
f CETP and lipoprotein donors and acceptors. When
mokers were excluded from the analysis, the CET rate in
atients with the lowest non–HDL-cholesterol and the
ETrameters
tween the CET
s or Lipid Parameters
Multivariate†
Model 1 Model 2
ion
ent
Standard
Error p Value
Regression
Coefficient
Standard
Error p Value
1 0.125 0.802 0.001 0.104 0.993
9 0.025 0.442 0.002 0.020 0.251
3 0.030 0.902 0.013 0.023 0.569
3 0.030 0.919 0.024 0.024 0.317
4 0.104 0.001 0.438 0.851 0.001
7 0.051 0.269 0.070 0.042 0.098
5 0.072 0.017 — — —
— — 0.163 0.050 0.001
1 0.121 0.007 0.399 0.099 0.001
7 0.512
ory of diabetes, hypertension, smoking, fibrate). †Multivariate analysis: multiple linear regression.
multiple linear regression analysis.
Figure 1 The Highest CET Rates Are Found
Among the Youngest Patients With First MI
Patients without a history of coronary artery disease (n  347) were divided
into tertiles of both non–high-density lipoprotein-cholesterol (HDL-c) and
HDL2b. The highest cholesteryl ester transfer (CET) rate (nmol/ml/h) was
observed in patients with the lowest HDL2b levels and the highest non–HDL-c
levels. Numbers at the top of each bar represent mean age to first myocardial
infarction (MI) (years). The subgroup with the highest CET rate contains the
youngest patients, with an 18-year difference from the subgroup with the low-
est CET rate (p  0.001). Non–HDL-c (mg/dl) tertiles: low 141, medium 142
to 180, and high 181. HDL2b (%) tertiles: low 14.48, medium 14.50 to
20.61, and high 20.72.he Cid Pa
n Be
ristic
egress
oeffici
0.03
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November 13, 2007:1948–55 CETP and Myocardial Infarctionighest HDL2b tertiles was still approximately one-half
hat of patients with the highest non–HDL-cholesterol and
he lowest HDL2b tertiles (n  228; 5.47  2.13 nmol/
l/h and 10.59 3.31 nmol/ml/h, respectively; p 0.001).
n the nonsmoking population, age at first MI in patients
ith the lowest CET rate was 10 years higher than that in
atients with the highest CET rate (74 11 years and 64
3 years, respectively; p  0.007). When patients treated
ith hypolipidemic drugs were excluded from the analysis,
omparison of CET rates still showed a significant differ-
nce between the lowest non–HDL-cholesterol/highest
DL2b group and the highest non–HDL-cholesterol/
owest HDL2b group (n  287; 5.72  2.53 nmol/ml/h
nd 12.79  3.91 nmol/ml/h, respectively; p  0.001).
gain, age at first MI in the lowest CET rate tertile was 18
ears higher than in the highest CET rate tertile (71  13
ears and 53  13 years, respectively; p  0.001). A
ignificant relationship between the CET rate and age at
I onset was observed whether patients with prior MI,
ocumented CHD, or peripheral vascular disease (n  132)
ere included (r  0.202; p  0.001; n  479) or were
ot included (r  0.261; p  0.001; n  347) in the
nalysis.
ender and CET rate. There was a trend toward a lower
roportion of women in the high-CET group (Table 1),
espite higher CETP levels in women than in men (Table 4).
hus, it was important to establish that the relationship
bserved between lipid parameters and age at MI onset did
ot relate to differences in the gender distribution across
ET tertiles. Table 6 shows blood lipid parameters in men
nd women. Women were older than men. They had higher
evels of HDL-cholesterol and large HDL and lower CET
ates and triglycerides-to-HDL-cholesterol ratios. Signifi-
ant negative correlations between CET rates and age at
ge and Blood Lipidarameters Stratified by Gender (n  347)
Table 6 Age and Blood LipidParameters Stratified by Gender (n  347)
Male, n  253 Female, n  94 p Value
Age at MI onset, yrs 60 14 71 13 0.001
Total cholesterol, mg/dl 204 42 200 48 0.454
LDL-cholesterol, mg/dl 138 36 129 46 0.058
HDL-cholesterol, mg/dl 38 13 45 15 0.001
Non–HDL-cholesterol, mg/dl 166 41 155 48 0.024
Triglycerides, mg/dl 142 92 132 107 0.249
TG:LDL-cholesterol ratio 1.04 0.62 1.08 0.85 0.879
TG:HDL-cholesterol ratio 4.70 4.61 3.45 3.45 0.005
CETP concentration, mg/l 2.67 0.56 3.06 0.63 0.001
CET rate, nmol/ml/h 8.50 3.11 7.67 2.79 0.028
HDL2a, % 27.7 4.9 27.0 3.6 0.216
HDL2b, % 16.7 6.9 20.3 5.8 0.001
HDL3a, % 27.3 4.7 25.8 3.2 0.001
HDL3b, % 17.6 4.9 16.6 3.6 0.088
HDL3c, % 10.6 4.5 10.3 4.3 0.804
LDL size, nm 25.4 0.6 25.6 0.5 0.016
alues are presented asmean SD. Continuous data were tested by either the Mann-Whitney rankp
um test or the Student t test as appropriate.
Abbreviations as in Tables 1 and 2.rst MI were found in both men and women, with an even
tronger negative correlation in women despite a smaller
ample size (men: r0.188; p 0.005; n 253; women:
 0.317; p  0.001; n  94).
iscussion
he present study specifically addressed an important yet
nanswered question: Are the highest levels of CETP
ssociated with a younger age among patients with first MI?
he CET rates between HDL and apoB-containing li-
oproteins have been characterized for the first time at the
arly phase of acute MI. Our findings demonstrate that the
ighest rates of CET are found among the youngest MI
atients, even when smokers, patients treated with hypo-
ipidemic drugs, or patients with prior cardiovascular disease
ere taken into account in the analysis. In addition, con-
ordant conclusions were drawn irrespective of gender.
ging has been shown to be accompanied by elevations in
lasma cholesterol and triglycerides, and by decreases in
DL-cholesterol and LDL size in healthy men and women
23–28). In contrast, in the present study age at MI onset
orrelated positively with HDL-cholesterol and HDL size,
ut negatively with triglycerides and non–HDL-cholesterol.
hus, lipoprotein changes did not relate to the aging process
er se, and findings should not be interpreted in terms of
ging but rather of time to MI onset. Our data further
upport the hypothesis that elevated CETP activity may
ctually provide a clue to the previously reported association
f high plasma triglyceride and low HDL-cholesterol levels
ith premature CHD (29). As an extension to recent
tudies in which high CETP levels were associated with
aster progression of atherosclerosis (9,11), the present
bservations lend further support of the hypothesis of a
elationship between a high serum CET rate and the earlier
isease onset among patients undergoing MI.
The controversy on the proatherogenic or antiatherogenic
roperty of CETP is based on the fact that its activity might
e highly dependent on the metabolic context. When
ssociated with the high VLDL/low HDL/small lipopro-
ein triad, CETP might act as a harmful proatherogenic
actor that accelerates cholesteryl ester flux from antiathero-
enic HDL to the accumulating triglyceride-rich apoB-
ontaining lipoproteins. Indeed, CETP has been found to
ncrease the risk for future CHD, but only in individuals
ith an accumulation of triglyceride-rich VLDL1 acceptors
8). In contrast, when clearance of VLDL and LDL is
ptimal, CETP might no longer act as a proatherogenic
actor, and may provide an alternative pathway for HDL
holesteryl esters to be removed from the bloodstream.
hen apoB-containing lipoprotein clearance was acceler-
ted by treatment with statins, the B1B1 Taq1B genotype
ith high CETP levels was not accompanied by an eleva-
ion in CHD risk (30). An inverse relationship was even
ound between the level of CETP expression and the
rogression of CHD (31) or the number of cardiovascular
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CETP and Myocardial Infarction November 13, 2007:1948–55vents (32) in statin-treated patients. Although CETP
oncentration is a major determinant of CET activity in
ivo, its activity is also dependent on lipoproteins. In an
ttempt to assess the combined effects of CETP concentra-
ion and the level and composition of lipoproteins in a
omprehensive way, the rate of CET from a tracer dose of
DL toward endogenous lipoprotein particles was mea-
ured in total serum in the present study. Our data also
evealed that MI patients were heterogeneous for both
ETP activity and lipoprotein profile. Compared with the
ower tertiles, the high CET rate group combined elevated
ETP and high triglyceride levels. These observations are
n agreement with a recent study that showed a synergistic
ontribution of CETP and triglycerides to an increased risk
f future CHD in apparently healthy individuals (8). The
ET assay used in the present study is assumed to closely
eflect the in vivo situation, in particular with regard to a key
ole of triglyceride-rich lipoproteins and CETP in driving
holesteryl esters out of HDL, resulting in shrinkage of the
articles (9,33–35). Accordingly, LDL and HDL shifted
oward small-sized particles in the high-CET group, pro-
iding further support to the hypothesis that elevated CET
ates were present before the index event. Because serum
esidence times of LDL and HDL are a few days (36,37),
DL and HDL size distributions can be considered as
emnant parameters and, as for standard lipid parameters,
ost likely reflect pre-MI values. The relative abundance of
mall LDL and HDL particles could therefore be consid-
red as an integrative marker of CETP activity. That small
DL size per se might directly account for higher CET
ates is excluded, because earlier studies in CETP transgenic
nimals (38) and in CETP-deficient patients (1) would have
redicted preferential interaction of CETP with large rather
han small HDL. Overall, and as predicted from mechanis-
ic studies (34), the size reduction in LDL and HDL in
atients with a high CET rate was likely to be driven by the
igh CETP/high triglyceride combination. Our data shed
ight on the complex association of small LDL and HDL
ith the risk of MI (5,6). Moreover, the opposite correla-
ions of the CET rate with either HDL3 or HDL2
ubpopulations further support the direct role of a high
ET rate in producing small HDL at the expense of large
DL. In addition, the present study suggests that the
DL2b subfraction, rather than LDL size might be a
eliable sensor of both high CET activity and increased risk
f MI in young patients. In this respect, the high CETP/
igh non–HDL-cholesterol/low HDL2b triad arises as the
est predictor of an elevated CET rate. Whereas triglycer-
des are probably a more potent driving factor of CETP
ctivity than non-HDL particles, most of the triglycerides
re more rapidly hydrolyzed in the blood stream, accounting
or the higher predictive value of the more stable non–
DL-cholesterol in the triad.
tudy limitations. As suggested by earlier studies,
ipoprotein-related parameters may vary over the few days
fter MI and thus constitute a potential confounding factor. Bowever, earlier reports indicated that lipid changes in
esponse to inflammation are only minor within the first
4 h of MI (15,16), leading us to systematically proceed to
lood sampling the day following the admission. Mean
ET rates in patients admitted in the second part of the
eriod studied, that is 12 to 24 h after MI, did not differ
ignificantly from those admitted earlier. Finally, the rela-
ionship between small lipoproteins and high CET rate
eported here is consistent with the expected trend. Thus, it
an be assumed that in the present study measurement of
ipoprotein parameters at the early phase of acute MI
pproximates accurately and in a retrospective manner the
hronic pre-MI lipoprotein profile.
Although the present study focused on first MI patients,
significant correlation between the CET rate and age at
I onset was still observed when patients with prior MI,
ocumented CHD or peripheral vascular disease were
dded into the analysis. Thus, the conclusions of the present
tudy might be extended beyond the population of patients
resenting with first MI.
Finally, although the observations of this study apply only
o patients who were hospitalized at the University Hospital
f Dijon and who survived acute MI until blood sampling,
hey could be generalized, because the population studied
ere shows the main features of contemporary MI registries
uch as GRACE (Global Registry of Acute Coronary
vents) (39) and NRMI (National Registry of Myocardial
nfarction) (40), in particular regarding age, gender, and risk
actors. In all cases, early in-hospital mortality (within 24 h)
as below 10%.
Although the method used to determine the CET rate
an be considered to be a valuable estimate of CETP activity
n vivo, it is highly dependent on triglyceride concentrations
n the medium. Furthermore, both CET rate and triglyc-
rides were found to independently predict age at first MI.
hus, it remains plausible that high triglycerides, in addition to
igh CET rate, might have contributed to the observed
elationship between CET rate and age. The causal relation-
hip between CETP activity and premature MI needs to be
urther investigated.
onclusions
he present study lends further support to the existence of
direct link between high CETP activity and the progres-
ion of CHD in humans, suggesting that the faster devel-
pment of atherosclerosis in patients with elevated CETP
ctivity could eventually translate into a younger age at the
rst acute coronary event.
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